Abstract 2044P
Background
BSI are a frequent and severe complication in cancer. Recent changes in oncological treatment, supportive care and development of new antimicrobial therapies could have affected its epidemiology, management and outcomes. Our aim is to describe clinical and microbiological features, antibiotic therapy, outcomes and mortality-related risk factors of BSI in cancer patients.
Methods
We performed a retrospective, observational, unicentric study. Microbiologically-confirmed BSI episodes in cancer patients between January 2017 and December 2021 were collected. We analysed clinical and microbiological data, empirical antibiotic treatment (EAT) and outcomes. A binary logistic regression model was used to detect variables related to 7 and 30-days mortality. P values <0.05 were considered significant.
Results
438 episodes of BSI were documented in 362 patients. Most frequent neoplasms were pancreatobiliary (25.1%), colorectal (16.9%), lung (11.9%) and breast (9.1%) tumours. 78.1% were metastatic. 72.1% had received chemotherapy in the previous month. The most common sources of BSI were vascular catheters (26.9%), cholangitis (23.1%) and other abdominal infections (22.8%). Gram-negative bacteria (GNB) were isolated in 60.3% of cases and Gram-positive bacteria in 45.4%. Yeasts were isolated in 3.9% of cases. Most common organisms were E. coli (29.7%), Klebsiella spp. (15.1%), coagulase-negative staphylococcus (12.6%) and S. aureus (10.3%). Most used EAT was piperacillin/tazobactam (43.2%), followed by meropenem (18.3%), amoxicilin/clavulanic acid (16%) and vancomycin (14.8%). Adequate EAT was given to 76.3% of patients. Mortality at 7 and 30 days was 11.2% and 24.4%, respectively. Statistical analysis showed lung cancer, respiratory source, yeasts and Pseudomonas spp. as independent risk factors for 7 and 20-days mortality.
Conclusions
BSI is a severe complication associated to elevated mortality in cancer patients. Most frequent sources of BSI are vascular catheters, cholangitis and abdominal infections. Most of them occur in patients with metastatic digestive tumours and are caused by GNB. Lung cancer, respiratory infections, isolation of yeasts and Pseudomonas spp. could imply a worse prognosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2106P - Safety and patient reported outcomes of SARS-CoV-2 vaccination in patients with cancer
Presenter: Amy Body
Session: Poster session 06
2107P - Thromboprophylaxis with intermediate or prophylactic doses of LMWHs in ambulatory cancer patients
Presenter: Nikolaos Tsoukalas
Session: Poster session 06
2108P - Vitamin B12 and its clinical relevance in hospitalized cancer patients
Presenter: Stefano Maccarone
Session: Poster session 06
2109P - Vitamin A, D and E levels in patients with solid tumors undergoing palliative systemic cancer treatment
Presenter: Julia Berger
Session: Poster session 06
2111P - The value of multiple psychometric tools for distress screening and referral in a cancer population
Presenter: Daniel Anderson
Session: Poster session 06
2112P - Initial geriatric assessment and chemotherapy tolerability treatment in Brazilian patients with malignant neoplasm of the digestive system
Presenter: Marcos Dumont Bonfin Santos
Session: Poster session 06
2113P - Efficacy and effectiveness of prophylactic magnesium supplementation on prevention of cisplatin-induced nephrotoxicity: A systematic review and meta-analysis
Presenter: Caio Castro
Session: Poster session 06
2114P - Impact of comprehensive geriatric assessment (CGA) in the management of chemotherapy toxicity in older cancer patients
Presenter: Jordi Recuero-Borau
Session: Poster session 06
2115P - Pre-cachexia incidence in patients with solid cancer: A cross-sectional study
Presenter: Lynn Gottmann
Session: Poster session 06